drugset / Trial / NCT05110898
Efficacy and Safety Study of the Fixed-dose Combination of Olmesartan + Indapamide When Compared to the Isolated Drugs in the Treatment of Hypertension.
RandomizedParallel-groupSingle-blindTreatment
Summary
Phase III clinical trial, multicenter of non-inferiority, randomized, single-blind evaluation of fixed-dose combination of olmesartan + indapamide compared to the isolated drugs in the treatment of hypertension.
Timeline
- Start
- 2022-08-01
- Primary completion
- 2023-08-01
- Completion
- 2023-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Indapamide | Small molecule | 1.5 mg | Oral |
| Subject | Olmesartan | Other / unclassified | 20 mg | Oral |
| Subject | Olmesartan | Other / unclassified | 40 mg | Oral |